Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Be Kind Clear all
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Momentary Coping Prompts and Hair Steroids in College Students

NCT07782398
View directory record Official record
Conditions
Emotional Regulation, Alcohol Drinking in College, Emotional Eating, Aggression
Interventions
Momentary coping prompt, Active control message
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 10, 2026, 5:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Botulinum Toxin Type A Injection After Topical Anesthesia Versus Petrolatum Ointment

NCT03799484
View directory record Official record
Conditions
Forehead Rhytides, Forehead Wrinkles
Interventions
Botulinum toxin type A, 2.5% lidocaine/2.5% prilocaine, petrolatum ointment
Drug · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Sep 10, 2026, 5:38 AM EDT
Completed Not applicable Interventional

Acupuncture for Prevention of Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy

NCT05975385
View directory record Official record
Conditions
Cholecystitis, Acute, Cholelithiasis, Nausea, Postoperative, Vomiting, Postoperative, Pain, Postoperative
Interventions
Acupuncture
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 10, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D)

NCT03263494
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
14 Years to 24 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 10, 2026, 5:38 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Perceptual Learning and Memory Consolidation in Adults With and Without LI

NCT03609502
View directory record Official record
Conditions
Language Development Disorders
Interventions
behavioral training
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 24 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 10, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

PDD in Type 2 Diabetes w/wo Diastolic Dysfunction

NCT03744975
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diastolic Dysfunction
Interventions
LCZ 696, Placebos
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 10, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification

NCT02100475
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Fresno, California • Fort Lauderdale, Florida • Gurnee, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 10, 2026, 5:38 AM EDT
Completed Not applicable Interventional

The Effect of Cross-Education on Shoulder Arthroscopy

NCT04470570
View directory record Official record
Conditions
Rotator Cuff Tears, Rotator Cuff Injuries, Rotator Cuff Repair
Interventions
Cross-Education, Blood-Flow Restriction Training
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Sep 10, 2026, 5:38 AM EDT
Recruiting Not applicable Interventional

Type 1 Diabetes and Obstructive Sleep Apnea

NCT06915831
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Type 1 Diabetes (T1D)
Interventions
Continuous positive airway pressure (CPAP)
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 10, 2026, 5:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

iSIPsmarter: An RCT Evaluating the Efficacy of a Technology-Based Intervention to Reduce Sugary Drinks in Rural Appalachia

NCT05030753
View directory record Official record
Conditions
Diet Habit, Sugar-Sweetened Beverages
Interventions
iSIPsmarter, Patient Education (PE)
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 110 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 10, 2026, 5:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of High Velocity/Hyperoxic Breathing Therapy on Blood Lactate Decline

NCT05984186
View directory record Official record
Conditions
Dyspnea, Lactic Acidosis, Muscle, Breathlessness, Exercise, Recovery
Interventions
High Velocity Therapy
Device
Lead sponsor
Vapotherm, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 10, 2026, 5:38 AM EDT
Suspended Phase 1Phase 2 Interventional

Dose Safety Hybrid Closed Loop and Fully Automated Closed Loop Artificial Pancreas Device in CRC

NCT03428295
View directory record Official record
Conditions
Glucose, Low Blood, Glucose, High Blood
Interventions
Dose Safety AP system
Device
Lead sponsor
Dose Safety Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 10, 2026, 5:38 AM EDT
Not listed Phase 2 Interventional

Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans

NCT02340845
View directory record Official record
Conditions
Cancer
Interventions
Bromelain and Comosain
Biological
Lead sponsor
Oeyama-Moto Cancer Research Foundation
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
West Covina, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Sep 10, 2026, 5:38 AM EDT
Enrolling by invitation Not applicable Interventional

Clinical Outcomes and Radiation Safety After Endovascular Repair of Complex AAAs Using Fenestrated- Branched Devices

NCT02266719
View directory record Official record
Conditions
Aortic Aneurysm, Abdominal, Thoracic Aneurysm
Interventions
Fenestrated CMD, Type I - III TAAA, Arch cohort
Device
Lead sponsor
Carlos Timaran
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
4
States / cities
Atlanta, Georgia • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 10, 2026, 5:38 AM EDT
Terminated Phase 1 Interventional

A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

NCT04999202
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BAY2416964, Pembrolizumab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Altamonte Springs, Florida • Sarasota, Florida • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 10, 2026, 5:38 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

NCT02174172
View directory record Official record
Conditions
Solid Cancers
Interventions
Atezolizumab, Bevacizumab, Interferon alfa-2b, Ipilimumab, Obinutuzumab, PEG-interferon alfa-2a
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 10, 2026, 5:38 AM EDT
Completed Not applicable Interventional

The Diabetes Medication Adherence Promotion Intervention Trial

NCT02458495
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes MAP Intervention
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 10, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

NCT00448201
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
10 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 10, 2026, 5:38 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Remote Ischemic Preconditioning Living Donor Renal Transplant Protocol

NCT03084666
View directory record Official record
Conditions
Renal Disease
Interventions
Zimmer ATS tourniquet system
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Sep 10, 2026, 5:38 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)

NCT02969356
View directory record Official record
Conditions
Spastic Hemiparesis
Interventions
Botulinum toxin type A, GSC
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Kansas City, Kansas • Pittsburgh, Pennsylvania • Charleston, South Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 10, 2026, 5:38 AM EDT
Active, not recruiting Phase 1 Interventional

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

NCT02160015
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Electrocardiogram, Ibrutinib, Lenalidomide, Magnetic Resonance Imaging, Rituximab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 10, 2026, 5:38 AM EDT
Completed Not applicable Interventional Results available

FLEX Vessel Prep Prior to Angioplasty in Native Arteriovenous Fistulae (AVF)

NCT05034939
View directory record Official record
Conditions
Arteriovenous Fistula Stenosis
Interventions
FLEX Vessel Prep System, Angioplasty
Device
Lead sponsor
VentureMed Group Inc.
Industry
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Phoenix, Arizona • Miami, Florida • New Brighton, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 10, 2026, 5:38 AM EDT
Terminated Phase 2 Interventional

Title XELOX FOR SALIVARY GLAND CANCERS

NCT00101075
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Capecitabine, Oxaliplatin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 10, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

Metformin Therapy for Overweight Adolescents With Type 1 Diabetes

NCT01881828
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Metformin (glucophage), oral placebo
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
12 Years to 19 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Sep 10, 2026, 5:38 AM EDT